SEC Comment Letter for Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259) (OTLC) — Nov 19, 2010

Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)
Date: Nov. 19, 2010 · CIK: 0000908259 · Accession: 0000000000-10-069686

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-21990

Date

Nov. 19, 2010

Author

Jeffrey Riedler

Form

UPLOAD

Company

Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)

Letter

Via Facsimile and U.S. Mail November 19 , 2010 James B. Murphy Vice President and Chief Financial Officer OXiGENE, Inc. 701 Gateway Boulevard, Suite 210 South San Francisco, CA 94080

Re: OXiGENE, Inc. Form 10 -K for the Fiscal Year Ended December 31 , 2009 Filed March 16 , 2010 File No. 000-21990

Dear Mr. Murphy :

We have comp leted our review of your filing and do not hav e any further comments at this time.

Sincerely,
Jeffrey Riedler
Assistant Director

Show Raw Text

Via Facsimile and U.S. Mail
November 19 , 2010

James B. Murphy
Vice President and Chief Financial Officer
OXiGENE, Inc.
701 Gateway Boulevard, Suite  210
South San  Francisco, CA 94080

Re: OXiGENE, Inc.
  Form 10 -K for the Fiscal Year Ended December 31 , 2009
  Filed March 16 , 2010
  File No. 000-21990

Dear  Mr. Murphy :

  We have comp leted our review of your filing  and do not hav e any further comments
at this time.

        Sincerely,

        Jeffrey Riedler
        Assistant Director

cc: Asya S. Alexandrovich , Esq ,
Mintz Levin Cohn Ferris Glovsky and Popeo P C
One Financial Center
Boston , Massachusetts  02111

SecProbe.io